Key result
Rimantadine therapy in patients with moderate influenza led to a statistically significant reduction in the duration of intoxication and catarrhal symptoms, and reduced the incidence of complications.
Why the study?
Does rimantadine reduce symptom duration and complications in patients with moderate influenza A?
Cohort (n=46)
Does rimantadine reduce symptom duration and complications in patients with moderate influenza A?
Rimantadine therapy is effective in reducing symptom duration and complications in patients with moderate influenza A.
No takes yet. Share an insight, caveat, or question.
Should not yet change influenza practice; leaves open need for RCTs to confirm benefit.
В. П. Малий (2017) conducted a cohort in Influenza (n=46). Rimantadine (Remavir) vs. Pathogenetic and symptomatic therapy was evaluated on Duration of symptoms of intoxication and catarrhal symptoms, and incidence of complications. Rimantadine therapy in patients with moderate influenza led to a statistically significant reduction in the duration of intoxication and catarrhal symptoms, and reduced the incidence of complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: